Gain Therapeutics, Inc. (GANX) Share-based Payment Arrangement, Expense USD 2021 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Gain Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2021 to 2024.
  • Gain Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $190 K, a 66.3% decline year-over-year.
  • Gain Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $2.88 M, a 61.5% increase year-over-year.
  • Gain Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3.26 M, a 114% increase from 2022.
  • Gain Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.53 M, a 81.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $2.88 M $190 K -$375 K -66.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $3.26 M $553 K -$5.59 K -1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 $3.26 M $816 K +$460 K +129% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $2.8 M $1.32 M +$1.02 M +333% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $1.79 M $565 K +$259 K +84.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $1.53 M $559 K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 $356 K +$105 K +41.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $306 K +$114 K +59.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $307 K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q3 2021 $251 K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $192 K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.